Asialoglycoprotein Receptor (ASGPR)

Asialoglycoprotein Receptor (ASGPR),又称 Ashwell-Morell 受体,是一种高度特异性表达于肝细胞表面的C型凝集素,是哺乳动物中最早被发现的细胞表面凝集素。ASGPR由两个亚基 (H1 和 H2) 组成,具有钙依赖性的碳水化合物识别结构域 (CRD),能识别去唾液酸糖蛋白上的D-半乳糖 (Gal) 或N-乙酰半乳糖胺 (GalNAc) 末端。
Asialoglycoprotein receptor (ASGPR) 通过网格蛋白介导的胞吞作用将配体内吞,胞吞后仍可循环利用,显示出高效的递送潜力。ASGPR 广泛参与去唾液酸糖蛋白的清除,如 IgA、细胞外纤维连接蛋白、肝脂蛋白等,同时也与病原体的肝细胞侵入相关。
由于ASGPR在肝细胞中的高表达 (约 50 万个/每肝细胞),且在其他组织中表达极低,因此成为理想的肝靶向递送靶点。基于 ASGPR 的化合物递送策略常利用天然或合成的糖类配体 (如arabinogalactan、pullulan、GalNAc 修饰聚合物等) 构建配体-化合物共轭物或纳米载体,实现高选择性的肝细胞摄取。
ASGPR 异常表达或功能障碍与多种疾病密切相关,如病毒性肝炎、肝癌、自身免疫性肝炎、糖尿病及药物性肝损伤等。ASGPR不仅是一个重要的研究靶点,也在肝功能评估与诊断中具有潜在价值[1]。

Asialoglycoprotein Receptor (ASGPR), also known as the Ashwell-Morell receptor, is a C-type lectin highly and specifically expressed on the surface of hepatocytes. It was the first cell surface lectin discovered in mammals. ASGPR is composed of two subunits (H1 and H2) and contains calcium-dependent carbohydrate recognition domains (CRDs) that can recognize terminal D-galactose (Gal) or N-acetylgalactosamine (GalNAc) residues on desialylated glycoproteins.
ASGPR mediates the internalization of its ligands via clathrin-mediated endocytosis and remains recyclable after internalization, showing great potential for efficient delivery. It plays a critical role in the clearance of desialylated glycoproteins such as IgA, extracellular fibronectin, and hepatic lipoproteins, and is also involved in the hepatic entry of certain pathogens.
Due to its high expression in hepatocytes (approximately 500,000 receptors per cell) and minimal expression in other tissues, ASGPR serves as an ideal target for liver-specific drug delivery. ASGPR-targeted delivery strategies often utilize natural or synthetic sugar-based ligands (e.g., arabinogalactan, pullulan, or GalNAc-modified polymers) to construct ligand-drug conjugates or ligand-anchored nanocarriers for selective uptake by hepatocytes.
Dysregulated expression or impaired function of ASGPR is closely associated with various diseases, including viral hepatitis, hepatocellular carcinoma, autoimmune hepatitis, diabetes, and drug-induced liver injury. ASGPR is not only a valuable therapeutic target but also holds potential in liver function evaluation and clinical diagnostics[1].

By Effects: Ligand (4)
共 4种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
ASGPR ligand-1

ASGPR ligand-1(Compound int-CC2)是一种去唾液酸糖蛋白受体(ASGPR)配体,其结合 Kd 值为 0.9 nM,可用于溶酶体降解相关疾病的研究。

1426160-58-8
Ligand
95.87%
ASGPR ligand-1
TMU454

TMU454 是一种 prototype GalNAc-PROTAC 偶联物,可与细胞膜上的 ASGPR 结合,并通过 ASGPR 介导的内吞作用被内化,从而选择性降解 BRD4,对肝细胞癌具有抗癌活性。

Ligand
TMU454
tri(GalNAc-PEG2)-PEG4-cyclo(Ac-DCAW-{Arg(3F-Ph)-PEG2}-LGELVWCT) (Cys2-Cys12)

tri(GalNAc-PEG2)-PEG4-cyclo(Ac-DCAW-{Arg(3F-Ph)-PEG2}-LGELVWCT) (Cys2-Cys12) 是一种去唾液酸糖蛋白受体 (ASGPR) 配体,可用于溶酶体靶向嵌合体 (LYTAC) 研究。

3099288-71-5
Ligand
99.46%
tri(GalNAc-PEG2)-PEG4-cyclo(Ac-DCAW-{Arg(3F-Ph)-PEG2}-LGELVWCT) (Cys2-Cys12)
tri-GalNAc-phosphoric acid

tri-GalNAc-phosphoric acid 是 ASGPR 的特异性配体,具备细胞特异性内化能力,可介导偶联的硬骨素适配体转运至表达 ASGPR 的细胞的溶酶体中,并可用于抗癌研究。

3084453-02-8
Ligand
tri-GalNAc-phosphoric acid

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础